Congenital hypogonadotropic hypogonadism: from clinical characteristics to genetic aspects

IF 1.9 Q2 MEDICINE, GENERAL & INTERNAL Precision and Future Medicine Pub Date : 2021-09-30 DOI:10.23838/pfm.2021.00093
A. Kwon, Ho-Seong Kim
{"title":"Congenital hypogonadotropic hypogonadism: from clinical characteristics to genetic aspects","authors":"A. Kwon, Ho-Seong Kim","doi":"10.23838/pfm.2021.00093","DOIUrl":null,"url":null,"abstract":"Congenital hypogonadotropic hypogonadism (CHH) is a rare disorder caused by a deficiency in gonadotropin-releasing hormone (GnRH). CHH is characterized by delayed puberty and/or infertility; this is because GnRH is the main component of the hypothalamic-pituitary-gonadal (HPG) axis, which is a key factor in pubertal development and reproductive function completion. However, since the development of sexual characteristics and reproduction begins in the prenatal period and is very complex and delicate, the clinical characteristics and involved genes are very diverse. In particular, the HPG axis is activated three times in a lifetime, and the symptoms and biochemical findings of CHH vary by period. In addition, related genes also vary according to the formation and activation process of the HPG axis. In this review, the clinical characteristics and treatment of CHH according to HPG axis activation and different developmental periods are reviewed, and the related genes are summarized according to their pathological mechanisms.","PeriodicalId":42462,"journal":{"name":"Precision and Future Medicine","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2021-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Precision and Future Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23838/pfm.2021.00093","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 2

Abstract

Congenital hypogonadotropic hypogonadism (CHH) is a rare disorder caused by a deficiency in gonadotropin-releasing hormone (GnRH). CHH is characterized by delayed puberty and/or infertility; this is because GnRH is the main component of the hypothalamic-pituitary-gonadal (HPG) axis, which is a key factor in pubertal development and reproductive function completion. However, since the development of sexual characteristics and reproduction begins in the prenatal period and is very complex and delicate, the clinical characteristics and involved genes are very diverse. In particular, the HPG axis is activated three times in a lifetime, and the symptoms and biochemical findings of CHH vary by period. In addition, related genes also vary according to the formation and activation process of the HPG axis. In this review, the clinical characteristics and treatment of CHH according to HPG axis activation and different developmental periods are reviewed, and the related genes are summarized according to their pathological mechanisms.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
先天性促性腺功能减退症:从临床特征到遗传因素
先天性促性腺功能减退症(CHH)是一种罕见的由促性腺激素释放激素(GnRH)缺乏引起的疾病。CHH的特征是青春期延迟和/或不孕;这是因为GnRH是下丘脑-垂体-性腺(HPG)轴的主要成分,是青春期发育和生殖功能完成的关键因素。然而,由于性特征和生殖的发展始于产前,并且非常复杂和微妙,因此临床特征和相关基因非常多样。特别是,HPG轴在一生中被激活三次,CHH的症状和生化结果因时期而异。此外,相关基因也随着HPG轴的形成和激活过程而变化。本文根据HPG轴激活和不同发育时期对CHH的临床特征和治疗进行了综述,并根据其病理机制对相关基因进行了综述。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Precision and Future Medicine
Precision and Future Medicine MEDICINE, GENERAL & INTERNAL-
自引率
0.00%
发文量
15
审稿时长
10 weeks
期刊最新文献
Survival rate and death risk for associated pulmonary arterial hypertension: A retrospective population-based study Understanding hikikomori syndrome in clinical settings: a case series Development of colistin resistance via heteroresistance modeling in Klebsiella pneumoniae: A diagnostic study Paraneoplastic neurological syndrome associated with onconeural autoantibodies: report of two cases Durable response to first-line treatment with AZD3759 (zorifertinib) in a patient with epithelial growth factor receptor mutated non-small cell lung cancer and untreated multiple brain metastasis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1